Copyright
©The Author(s) 2024.
World J Gastrointest Pharmacol Ther. Sep 5, 2024; 15(5): 95467
Published online Sep 5, 2024. doi: 10.4292/wjgpt.v15.i5.95467
Published online Sep 5, 2024. doi: 10.4292/wjgpt.v15.i5.95467
Episode | Treatment modality |
First recurrence | Vancomycin 125 mg orally 4 times a day for 10 days |
Fidaxomicin 200 mg orally 2 times a day for 10 days | |
Adjunctive therapy: Bezlotoxumab 10 mg/kg IV one time dose | |
Second recurrence | Tapered or pulsed vancomycin regimen |
Vancomycin 125 mg orally 4 times a day for 10 days, then rifaximin 400 mg three times daily for 20 days | |
Fidaxomicin 200 mg orally 2 times a day for 10 days | |
Adjunctive therapy: Bezlotoxumab 10 mg/kg IV one time dose | |
Third or more recurrence | Fecal microbiota transplant |
Adjunctive therapy: Bezlotoxumab 10 mg/kg IV one time dose |
- Citation: Nagesh VK, Tran HHV, Elias D, Kianifar Aguilar I, Sethi T, Menon A, Mansour C, Furman F, Tsotsos K, Subar T, Auda A, Sidiqui A, Lamar J, Wadhwani N, Dey S, Lo A, Atoot A, Weissman S, Sifuentes H, Bangolo AI. Therapeutics involved in managing initial and recurrent Clostridium difficile infection: An updated literature review. World J Gastrointest Pharmacol Ther 2024; 15(5): 95467
- URL: https://www.wjgnet.com/2150-5349/full/v15/i5/95467.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v15.i5.95467